查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2132310

人工視網膜市場規模、佔有率和趨勢分析報告：按產品、疾病、應用、地區和細分市場分類（2027-2033 年）

Artificial Retina Market Size, Share & Trends Analysis Report By Product, By Disease Indication, By End-use, By Region, And Segment Forecasts, 2027 - 2033
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

人工視網膜市場概述

2026 年全球人工視網膜市場價值為 330 萬美元，預計將從 2027 年的 690 萬美元成長到 2033 年的 2,520 萬美元，2027 年至 2033 年的複合年成長率為 33.6%。

到2026年，歐洲將主導市場，佔100%的銷售佔有率。人工視網膜系統，也稱為視網膜人工替代物或視網膜植入，是一種可植入的電子設備，旨在當感光細胞永久受損時，刺激剩餘的視網膜神經元和下游視覺通路。

這些系統通常由可植入的微電子晶片、外部攝影機、影像處理單元和無線通訊技術組成，它們協同工作，將視覺資訊轉換為視覺系統可以解讀的電訊號。目前，人工視網膜系統的商業性化仍處於起步階段。截至2026年，PRIMA是唯一一款獲得CE認證並於2026年7月上市的人工視網膜系統，用於治療乾性皮膚老齡化黃斑部病變的地圖狀萎縮。

目前，該產品的商業供應僅限於歐洲，初期部署主要集中在部分視網膜專科中心，但全部區域的保險報銷流程和更廣泛的部署地點正在逐步完善。由於商業性應用有限以及策略性商業決策，包括Argus II、Alpha IMS、Alpha AMS和IRIS II系統在內的老一代視網膜人工替代物已停產，導致過去和現在的商業化之間存在顯著差距。因此，全球人工視網膜產業目前主要由PRIMA在歐洲的初步商業化推動，未來的市場擴張預計將取決於進一步的法規核准、區域擴張、保險覆蓋範圍以及下一代視網膜人工替代物技術的商業化。

人工視網膜植入（ARI）技術主要針對視網膜色素變性（RP）、進行性老齡化黃斑部病變（AMD）、斯特格氏黃斑失養症和其他遺傳性視網膜營養不良患者而開發。對於這些患者而言，傳統的藥物或手術治療視力恢復的可能性有限甚至沒有希望。神經技術、生物電子學和視力恢復研究領域投入的不斷增加，正在推動人工視網膜植入（ARI）市場的持續發展。推動市場成長的主要因素之一是全球視網膜退化性疾病盛行率的不斷上升。遺傳性視網膜退化影響全球超過550萬人，而老齡化黃斑部病變仍是老年人不可逆性失明的主要原因之一。

人口老化、人們對遺傳性視網膜疾病的認知不斷提高、基因檢測技術的進步以及早期診斷的普及，使得更多患者能夠受益於先進的視力恢復技術。例如，2026年1月，《新英格蘭醫學日誌》（NEJM）發表了PRIMA臨床試驗的結果及相關社論，指出PRIMA視網膜下光電植入是首個用於治療由老齡化黃斑部病變（AMD）引起的進行性地圖狀萎縮患者的治療方法。該研究表明，大多數接受植入的患者視力均顯著改善，這標誌著人工視網膜技術和視力恢復研究領域的一個重要里程碑。

另一主要驅動力是視網膜人工替代物技術和神經工程的快速發展。微電子、光電植入、無線電力傳輸、高密度電極陣列、人工智慧影像處理以及小型化植入設計等領域的持續創新，顯著提高了人工視網膜系統的性能和安全性。與前幾代視網膜人工替代物相比，這些技術進步實現了更高的視覺解析度、更佳的植入穩定性以及更好的患者預後。

目錄

第1章：調查方法和範圍

第2章執行摘要

第3章：人工視網膜市場：變數、趨勢與範圍

  • 市場譜系展望
  • 市場動態
  • 人工視網膜市場分析工具

第4章 視網膜假體市場：依產品分類的估算與趨勢分析

  • 人工視網膜市場：依產品分類的趨勢分析
  • 人工視網膜市場：按產品分類的展望
  • 市場規模、預測與趨勢分析（2027-2033年）
  • 視網膜植入
  • 視網膜下植入
  • 脈絡膜植入

第5章：適用於人工視網膜的疾病的估計和趨勢分析

  • 人工視網膜市場：依疾病適應症分類的趨勢分析
  • 人工視網膜市場：依疾病適應症分類的展望
  • 市場規模、預測與趨勢分析（2027-2033年）
  • 色素性視網膜炎
    • 市場收入估算與預測（2027-2033 年）
  • 老齡化黃斑部病變（AMD）（地圖狀萎縮）
    • 市場收入估算與預測（2027-2033 年）
  • 斯特格氏黃斑失養症
    • 市場獲利預測（2027-2033）
  • 其他遺傳性視網膜營養不良（IRD）
    • 市場收入估算與預測（2027-2033 年）

第6章 視網膜假體市場：依最終用途分類的估算與趨勢分析

  • 視網膜假體市場：依最終用途分類的趨勢分析
  • 視網膜假體市場：依最終用途分類的展望
  • 市場規模、預測與趨勢分析（2027-2033年）
  • 醫院
  • 專科眼科診所
  • 其他

第7章：視網膜假體市場：區域估算與趨勢分析

  • 區域儀錶板
  • 人工視網膜市場波動區域分析
  • 人工視網膜市場：區域估算與趨勢分析
  • 市場規模、預測與趨勢分析（2027-2033年）
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • UAE
    • 科威特

第8章 競爭情勢

  • 參與企業的分類
  • 主要公司簡介
    • Science Corporation
    • Cortigent（Subsidiary of Vivani Medical, Inc.）
    • Nano Retina
    • Bionic Vision Technologies
    • iBIONICS
    • Optobionics Corporation
    • Monash Vision Group
    • NIDEK CO., LTD.
Product Code: GVR-4-68041-000-2

Artificial Retina Market Summary

The global artificial retina market size is valued at USD 3.3 million in 2026 and is projected to grow from USD 6.9 million in 2027 to USD 25.2 million by 2033, at a CAGR of 33.6% from 2027 to 2033. Europe dominated the market, accounting for the largest revenue share of 100.0% in 2026. Artificial retina systems, also known as retinal prostheses or retinal implants, are implantable electronic devices designed to stimulate surviving retinal neurons or downstream visual pathways when photoreceptor cells have been permanently damaged.

These systems typically comprise an implantable microelectronic chip, an external camera, an image processing unit, and wireless communication technology that together convert visual information into electrical signals interpretable by the visual system. The current commercial landscape for artificial retina systems remains highly nascent. As of 2026, PRIMA is the only artificial retina system that has entered commercialization, following the receipt of CE Mark approval in July 2026 for the treatment of geographic atrophy secondary to dry age-related macular degeneration.

Commercial availability is currently limited to Europe, with initial rollout focused on selected specialized retinal centers while reimbursement processes and broader site activation continue across the region. Earlier-generation retinal prostheses, including the Argus II, Alpha IMS, Alpha AMS, and IRIS II systems, have been discontinued due to limited commercial adoption and strategic business decisions, resulting in a significant gap between historical and current commercialization. Consequently, the global artificial retina industry is presently driven primarily by the initial European commercialization of PRIMA, with future market expansion expected to depend on additional regulatory approvals, geographic expansion, reimbursement adoption, and the commercialization of next-generation retinal prosthesis technologies.

Artificial retina implant (ARI) technologies are primarily being developed for patients with retinitis pigmentosa (RP), advanced age-related macular degeneration (AMD), Stargardt disease, and other inherited retinal dystrophies, for whom conventional medical or surgical treatments offer limited or no restoration of vision. Growing investments in neurotechnology, bioelectronics, and vision restoration research are supporting the continued development of the artificial retina implant (ARI) market. One of the primary factors driving market growth is the increasing prevalence of retinal degenerative diseases globally. Inherited retinal degenerations affect more than 5.5 million people globally, while age-related macular degeneration remains one of the leading causes of irreversible blindness among older adults.

Population aging, greater awareness of inherited retinal disorders, improved genetic testing, and earlier diagnosis are expanding the pool of patients who may benefit from advanced vision restoration technologies. For instance, In January 2026, the New England Journal of Medicine (NEJM) published the PRIMA clinical trial and an accompanying editorial recognizing the PRIMA subretinal photovoltaic implant as the first treatment to restore vision in patients with advanced geographic atrophy due to age-related macular degeneration (AMD). The study demonstrated clinically meaningful improvements in visual acuity in the majority of implanted patients, marking a significant milestone in the advancement of artificial retina technology and vision restoration research.

Another major driver is the rapid advancement of retinal prosthesis technology and neuroengineering. Continuous innovations in microelectronics, photovoltaic implants, wireless power transfer, high-density electrode arrays, artificial intelligence-enabled image processing, and miniaturized implant designs are significantly improving the performance and safety of artificial retina systems. These technological developments are enabling higher visual resolution, improved implant stability, and enhanced patient outcomes compared with earlier generations of retinal prostheses.

Global Artificial Retina Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2027 to 2033. For this study, Grand View Research has segmented the global artificial retina market report based on product, disease indication, end-use, and region:

  • Product Outlook (Revenue, USD Million, 2027 - 2033)
  • Epiretinal Implants
  • Subretinal Implants
  • Suprachoroidal Implants
  • Disease Indication Outlook (Revenue, USD Million, 2027 - 2033)
  • Retinitis Pigmentosa
  • Dry Age-Related Macular Degeneration (Geographic Atrophy)
  • Stargardt disease
  • Other Inherited Retinal Dystrophies (IRD)
  • End Use Outlook (Revenue, USD Million, 2027 - 2033)
  • Hospitals
  • Specialty Eye Clinics
  • Others
  • Regional Outlook (Revenue, USD Million, 2027 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Norway
    • Denmark
    • Sweden
  • Asia Pacific
    • China
    • Japan
    • South Korea
    • Thailand
    • Australia
    • India
  • Latin America
    • Brazil
    • Argentina
  • MEA
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Disease Indication
    • 1.2.3. End Use
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product outlook
    • 2.2.2. Disease Indication outlook
    • 2.2.3. End Use outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Artificial Retina Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Artificial Retina Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Bargaining power of suppliers
      • 3.3.1.2. Bargaining power of buyers
      • 3.3.1.3. Threat of substitutes
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic landscape
      • 3.3.2.3. Social landscape
      • 3.3.2.4. Technological landscape
      • 3.3.2.5. Environmental landscape
      • 3.3.2.6. Legal landscape

Chapter 4. Artificial Retina Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Artificial Retina Market: Product Movement Analysis
  • 4.3. Artificial Retina Market by Product Outlook (USD Million)
  • 4.4. Market Size & Forecasts and Trend Analyses, 2027 to 2033 for the following
  • 4.5. Epiretinal Implants
    • 4.5.1. Market Revenue Estimates and Forecasts, 2027 - 2033 (USD Million)
  • 4.6. Subretinal Implants
    • 4.6.1. Market Revenue Estimates and Forecasts, 2027 - 2033 (USD Million)
  • 4.7. Suprachoroidal Implants
    • 4.7.1. Market Revenue Estimates and Forecasts, 2027 - 2033 (USD Million)

Chapter 5. Artificial Retina MaDisease Indication Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Artificial Retina Market: Disease Indication Movement Analysis
  • 5.3. Artificial Retina Market by Disease Indication Outlook (USD Million)
  • 5.4. Market Size & Forecasts and Trend Analyses, 2027 to 2033 for the following
  • 5.5. Retinitis Pigmentosa
    • 5.5.1. Market Revenue Estimates and Forecasts, 2027 - 2033 (USD Million)
  • 5.6. Dry Age-Related Macular Degeneration (AMD) (Geographic Atrophy)
    • 5.6.1. Market Revenue Estimates and Forecasts, 2027 - 2033 (USD Million)
  • 5.7. Stargardt disease
    • 5.7.1. Market Revenue Estimates and Forecasts, 2027 - 2033 (USD Million)
  • 5.8. Other Inherited Retinal Dystrophies (IRD)
    • 5.8.1. Market Revenue Estimates and Forecasts, 2027 - 2033 (USD Million)

Chapter 6. Artificial Retina Market: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Artificial Retina Market: End Use Movement Analysis
  • 6.3. Artificial Retina Market by End Use Outlook (USD Million)
  • 6.4. Market Size & Forecasts and Trend Analyses, 2027 to 2033 for the following
  • 6.5. Hospitals
    • 6.5.1. Market Revenue Estimates and Forecasts, 2027 - 2033 (USD Million)
  • 6.6. Specialty Eye Clinics
    • 6.6.1. Market Revenue Estimates and Forecasts, 2027 - 2033 (USD Million)
  • 6.7. Others
    • 6.7.1. Market Revenue Estimates and Forecasts, 2027 - 2033 (USD Million)

Chapter 7. Artificial Retina Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Dashboard
  • 7.2. Regional Artificial Retina Market Movement Analysis
  • 7.3. Artificial Retina Market: Regional Estimates & Trend Analysis by Product & Disease Indication
  • 7.4. Market Size & Forecasts and Trend Analyses, 2027 to 2033 for the following
  • 7.5. North America
    • 7.5.1. North America Artificial Retina Market Estimates and Forecasts, 2027 - 2033 (USD Million)
    • 7.5.2. U.S.
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Competitive Scenario
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Reimbursement scenario
      • 7.5.2.5. U.S. Artificial Retina Market Estimates and Forecasts, 2027 - 2033 (USD Million)
    • 7.5.3. Canada
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Competitive Scenario
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. Reimbursement scenario
      • 7.5.3.5. Canada Artificial Retina Market Estimates and Forecasts, 2027 - 2033 (USD Million)
    • 7.5.4. Mexico
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Competitive Scenario
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. Reimbursement scenario
      • 7.5.4.5. Mexico Artificial Retina Market Estimates and Forecasts, 2027 - 2033 (USD Million)
  • 7.6. Europe
    • 7.6.1. Europe Artificial Retina Market Estimates and Forecasts, 2027 - 2033 (USD Million)
    • 7.6.2. UK
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Competitive Scenario
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Reimbursement scenario
      • 7.6.2.5. UK Artificial Retina Market Estimates and Forecasts, 2027 - 2033 (USD Million)
    • 7.6.3. Germany
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Competitive Scenario
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Reimbursement scenario
      • 7.6.3.5. Germany Artificial Retina Market Estimates and Forecasts, 2027 - 2033 (USD Million)
    • 7.6.4. France
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Competitive Scenario
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. Reimbursement scenario
      • 7.6.4.5. France Artificial Retina Market Estimates and Forecasts, 2027 - 2033 (USD Million)
    • 7.6.5. Italy
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Competitive Scenario
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Reimbursement scenario
      • 7.6.5.5. Italy Artificial Retina Market Estimates and Forecasts, 2027 - 2033 (USD Million)
    • 7.6.6. Spain
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Competitive Scenario
      • 7.6.6.3. Regulatory Framework
      • 7.6.6.4. Reimbursement scenario
      • 7.6.6.5. Spain Artificial Retina Market Estimates and Forecasts, 2027 - 2033 (USD Million)
    • 7.6.7. Denmark
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Competitive Scenario
      • 7.6.7.3. Regulatory Framework
      • 7.6.7.4. Reimbursement scenario
      • 7.6.7.5. Denmark Artificial Retina Market Estimates and Forecasts, 2027 - 2033 (USD Million)
    • 7.6.8. Sweden
      • 7.6.8.1. Key Country Dynamics
      • 7.6.8.2. Competitive Scenario
      • 7.6.8.3. Regulatory Framework
      • 7.6.8.4. Reimbursement scenario
      • 7.6.8.5. Sweden Artificial Retina Market Estimates and Forecasts, 2027 - 2033 (USD Million)
    • 7.6.9. Norway
      • 7.6.9.1. Key Country Dynamics
      • 7.6.9.2. Competitive Scenario
      • 7.6.9.3. Regulatory Framework
      • 7.6.9.4. Reimbursement scenario
      • 7.6.9.5. Norway Artificial Retina Market Estimates and Forecasts, 2027 - 2033 (USD Million)
  • 7.7. Asia Pacific
    • 7.7.1. Asia Pacific Artificial Retina Market Estimates and Forecasts, 2027 - 2033 (USD Million)
    • 7.7.2. Japan
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Competitive Scenario
      • 7.7.2.3. Regulatory Framework
      • 7.7.2.4. Reimbursement scenario
      • 7.7.2.5. Japan Artificial Retina Market Estimates and Forecasts, 2027 - 2033 (USD Million)
    • 7.7.3. China
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Competitive Scenario
      • 7.7.3.3. Regulatory Framework
      • 7.7.3.4. Reimbursement scenario
      • 7.7.3.5. China Artificial Retina Market Estimates and Forecasts, 2027 - 2033 (USD Million)
    • 7.7.4. India
      • 7.7.4.1. Key Country Dynamics
      • 7.7.4.2. Competitive Scenario
      • 7.7.4.3. Regulatory Framework
      • 7.7.4.4. Reimbursement scenario
      • 7.7.4.5. India Artificial Retina Market Estimates and Forecasts, 2027 - 2033 (USD Million)
    • 7.7.5. South Korea
      • 7.7.5.1. Key Country Dynamics
      • 7.7.5.2. Competitive Scenario
      • 7.7.5.3. Regulatory Framework
      • 7.7.5.4. Reimbursement scenario
      • 7.7.5.5. South Korea Artificial Retina Market Estimates and Forecasts, 2027 - 2033 (USD Million)
    • 7.7.6. Australia
      • 7.7.6.1. Key Country Dynamics
      • 7.7.6.2. Competitive Scenario
      • 7.7.6.3. Regulatory Framework
      • 7.7.6.4. Reimbursement scenario
      • 7.7.6.5. Australia Artificial Retina Market Estimates and Forecasts, 2027 - 2033 (USD Million)
    • 7.7.7. Thailand
      • 7.7.7.1. Key Country Dynamics
      • 7.7.7.2. Competitive Scenario
      • 7.7.7.3. Regulatory Framework
      • 7.7.7.4. Reimbursement scenario
      • 7.7.7.5. Thailand Artificial Retina Market Estimates and Forecasts, 2027 - 2033 (USD Million)
  • 7.8. Latin America
    • 7.8.1. Latin America Artificial Retina Market Estimates and Forecasts, 2027 - 2033 (USD Million)
    • 7.8.2. Brazil
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Competitive Scenario
      • 7.8.2.3. Regulatory Framework
      • 7.8.2.4. Reimbursement scenario
      • 7.8.2.5. Brazil Artificial Retina Market Estimates and Forecasts, 2027 - 2033 (USD Million)
    • 7.8.3. Argentina
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Competitive Scenario
      • 7.8.3.3. Regulatory Framework
      • 7.8.3.4. Reimbursement scenario
      • 7.8.3.5. Argentina Artificial Retina Market Estimates and Forecasts, 2027 - 2033 (USD Million)
  • 7.9. Middle East & Africa
    • 7.9.1. Middle East & Africa Artificial Retina Market Estimates and Forecasts, 2027 - 2033 (USD Million)
    • 7.9.2. South Africa
      • 7.9.2.1. Key Country Dynamics
      • 7.9.2.2. Competitive Scenario
      • 7.9.2.3. Regulatory Framework
      • 7.9.2.4. Reimbursement scenario
      • 7.9.2.5. South Africa Artificial Retina Market Estimates and Forecasts, 2027 - 2033 (USD Million)
    • 7.9.3. Saudi Arabia
      • 7.9.3.1. Key Country Dynamics
      • 7.9.3.2. Competitive Scenario
      • 7.9.3.3. Regulatory Framework
      • 7.9.3.4. Reimbursement scenario
      • 7.9.3.5. Saudi Arabia Artificial Retina Market Estimates and Forecasts, 2027 - 2033 (USD Million)
    • 7.9.4. UAE
      • 7.9.4.1. Key Country Dynamics
      • 7.9.4.2. Competitive Scenario
      • 7.9.4.3. Regulatory Framework
      • 7.9.4.4. Reimbursement scenario
      • 7.9.4.5. UAE Artificial Retina Market Estimates and Forecasts, 2027 - 2033 (USD Million)
    • 7.9.5. Kuwait
      • 7.9.5.1. Key Country Dynamics
      • 7.9.5.2. Competitive Scenario
      • 7.9.5.3. Regulatory Framework
      • 7.9.5.4. Reimbursement scenario
      • 7.9.5.5. Kuwait Artificial Retina Market Estimates and Forecasts, 2027 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Market Participant Categorization
  • 8.2. Key Company Profiles
    • 8.2.1. Science Corporation
      • 8.2.1.1. Company Overview
      • 8.2.1.2. Financial Performance
      • 8.2.1.3. Product Benchmarking
      • 8.2.1.4. Strategic Initiatives
    • 8.2.2. Cortigent (Subsidiary of Vivani Medical, Inc.)
      • 8.2.2.1. Company Overview
      • 8.2.2.2. Financial Performance
      • 8.2.2.3. Product Benchmarking
      • 8.2.2.4. Strategic Initiatives
    • 8.2.3. Nano Retina
      • 8.2.3.1. Company Overview
      • 8.2.3.2. Financial Performance
      • 8.2.3.3. Product Benchmarking
      • 8.2.3.4. Strategic Initiatives
    • 8.2.4. Bionic Vision Technologies
      • 8.2.4.1. Company Overview
      • 8.2.4.2. Financial Performance
      • 8.2.4.3. Product Benchmarking
      • 8.2.4.4. Strategic Initiatives
    • 8.2.5. iBIONICS
      • 8.2.5.1. Company Overview
      • 8.2.5.2. Financial Performance
      • 8.2.5.3. Product Benchmarking
      • 8.2.5.4. Strategic Initiatives
    • 8.2.6. Optobionics Corporation
      • 8.2.6.1. Company Overview
      • 8.2.6.2. Financial Performance
      • 8.2.6.3. Product Benchmarking
      • 8.2.6.4. Strategic Initiatives
    • 8.2.7. Monash Vision Group
      • 8.2.7.1. Company Overview
      • 8.2.7.2. Financial Performance
      • 8.2.7.3. Product Benchmarking
      • 8.2.7.4. Strategic Initiatives
    • 8.2.8. NIDEK CO., LTD.
      • 8.2.8.1. Company Overview
      • 8.2.8.2. Financial Performance
      • 8.2.8.3. Product Benchmarking
      • 8.2.8.4. Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Artificial Retina Market, by Product, 2027 - 2033 (USD Million)
  • Table 4 Global Artificial Retina Market, by Disease Indication, 2027 - 2033 (USD Million)
  • Table 5 Global Artificial Retina Market, by End Use, 2027 - 2033 (USD Million)
  • Table 6 North America Artificial Retina Market, by Country, 2027 - 2033 (USD Million)
  • Table 7 North America Artificial Retina Market, by Product, 2027 - 2033 (USD Million)
  • Table 8 North America Artificial Retina Market, by Disease Indication, 2027 - 2033 (USD Million)
  • Table 9 North America Artificial Retina Market, by End Use, 2027 - 2033 (USD Million)
  • Table 10 U.S. Artificial Retina Market, by Product, 2027 - 2033 (USD Million)
  • Table 11 U.S. Artificial Retina Market, by Disease Indication, 2027 - 2033 (USD Million)
  • Table 12 U.S. Artificial Retina Market, by End Use, 2027 - 2033 (USD Million)
  • Table 13 Canada Artificial Retina Market, by Product, 2027 - 2033 (USD Million)
  • Table 14 Canada Artificial Retina Market, by Disease Indication, 2027 - 2033 (USD Million)
  • Table 15 Canada Artificial Retina Market, by End Use, 2027 - 2033 (USD Million)
  • Table 16 Mexico Artificial Retina Market, by Product, 2027 - 2033 (USD Million)
  • Table 17 Mexico Artificial Retina Market, by Disease Indication, 2027 - 2033 (USD Million)
  • Table 18 Mexico Artificial Retina Market, by End Use, 2027 - 2033 (USD Million)
  • Table 19 Europe Artificial Retina Market, by Country, 2027 - 2033 (USD Million)
  • Table 20 Europe Artificial Retina Market, by Product, 2027 - 2033 (USD Million)
  • Table 21 Europe Artificial Retina Market, by Disease Indication, 2027 - 2033 (USD Million)
  • Table 22 Europe Artificial Retina Market, by End Use, 2027 - 2033 (USD Million)
  • Table 23 Germany Artificial Retina Market, by Product, 2027 - 2033 (USD Million)
  • Table 24 Germany Artificial Retina Market, by Disease Indication, 2027 - 2033 (USD Million)
  • Table 25 Germany Artificial Retina Market, by End Use, 2027 - 2033 (USD Million)
  • Table 26 Spain Artificial Retina Market, by Product, 2027 - 2033 (USD Million)
  • Table 27 Spain Artificial Retina Market, by Disease Indication, 2027 - 2033 (USD Million)
  • Table 28 Spain Artificial Retina Market, by End Use, 2027 - 2033 (USD Million)
  • Table 29 UK Artificial Retina Market, by Product, 2027 - 2033 (USD Million)
  • Table 30 UK Artificial Retina Market, by Disease Indication, 2027 - 2033 (USD Million)
  • Table 31 UK Artificial Retina Market, by End Use, 2027 - 2033 (USD Million)
  • Table 32 Italy Artificial Retina Market, by Product, 2027 - 2033 (USD Million)
  • Table 33 Italy Artificial Retina Market, by Disease Indication, 2027 - 2033 (USD Million)
  • Table 34 Italy Artificial Retina Market, by End Use, 2027 - 2033 (USD Million)
  • Table 35 France Artificial Retina Market, by Product, 2027 - 2033 (USD Million)
  • Table 36 France Artificial Retina Market, by Disease Indication, 2027 - 2033 (USD Million)
  • Table 37 France Artificial Retina Market, by End Use, 2027 - 2033 (USD Million)
  • Table 38 Denmark Artificial Retina Market, by Product, 2027 - 2033 (USD Million)
  • Table 39 Denmark Artificial Retina Market, by Disease Indication, 2027 - 2033 (USD Million)
  • Table 40 Denmark Artificial Retina Market, by End Use, 2027 - 2033 (USD Million)
  • Table 41 Sweden Artificial Retina Market, by Product, 2027 - 2033 (USD Million)
  • Table 42 Sweden Artificial Retina Market, by Disease Indication, 2027 - 2033 (USD Million)
  • Table 43 Sweden Artificial Retina Market, by End Use, 2027 - 2033 (USD Million)
  • Table 44 Norway Artificial Retina Market, by Product, 2027 - 2033 (USD Million)
  • Table 45 Norway Artificial Retina Market, by Disease Indication, 2027 - 2033 (USD Million)
  • Table 46 Norway Artificial Retina Market, by End Use, 2027 - 2033 (USD Million)
  • Table 47 Asia Pacific Artificial Retina Market, by Country, 2027 - 2033 (USD Million)
  • Table 48 Asia Pacific Artificial Retina Market, by Product, 2027 - 2033 (USD Million)
  • Table 49 Asia Pacific Artificial Retina Market, by Disease Indication, 2027 - 2033 (USD Million)
  • Table 50 Asia Pacific Artificial Retina Market, by End Use, 2027 - 2033 (USD Million)
  • Table 51 India Artificial Retina Market, by Product, 2027 - 2033 (USD Million)
  • Table 52 India Artificial Retina Market, by Disease Indication, 2027 - 2033 (USD Million)
  • Table 53 India Artificial Retina Market, by End Use, 2027 - 2033 (USD Million)
  • Table 54 Japan Artificial Retina Market, by Product, 2027 - 2033 (USD Million)
  • Table 55 Japan Artificial Retina Market, by Disease Indication, 2027 - 2033 (USD Million)
  • Table 56 Japan Artificial Retina Market, by End Use, 2027 - 2033 (USD Million)
  • Table 57 China Artificial Retina Market, by Product, 2027 - 2033 (USD Million)
  • Table 58 China Artificial Retina Market, by Disease Indication, 2027 - 2033 (USD Million)
  • Table 59 China Artificial Retina Market, by End Use, 2027 - 2033 (USD Million)
  • Table 60 Australia Artificial Retina Market, by Product, 2027 - 2033 (USD Million)
  • Table 61 Australia Artificial Retina Market, by Disease Indication, 2027 - 2033 (USD Million)
  • Table 62 Australia Artificial Retina Market, by End Use, 2027 - 2033 (USD Million)
  • Table 63 South Korea Artificial Retina Market, by Product, 2027 - 2033 (USD Million)
  • Table 64 South Korea Artificial Retina Market, by Disease Indication, 2027 - 2033 (USD Million)
  • Table 65 South Korea Artificial Retina Market, by End Use, 2027 - 2033 (USD Million)
  • Table 66 Thailand Artificial Retina Market, by Product, 2027 - 2033 (USD Million)
  • Table 67 Thailand Artificial Retina Market, by Disease Indication, 2027 - 2033 (USD Million)
  • Table 68 Thailand Artificial Retina Market, by End Use, 2027 - 2033 (USD Million)
  • Table 69 Latin America Artificial Retina Market, by Country, 2027 - 2033 (USD Million)
  • Table 70 Latin America Artificial Retina Market, by Product, 2027 - 2033 (USD Million)
  • Table 71 Latin America Artificial Retina Market, by Disease Indication, 2027 - 2033 (USD Million)
  • Table 72 Latin America Artificial Retina Market, by End Use, 2027 - 2033 (USD Million)
  • Table 73 Argentina Artificial Retina Market, by Product, 2027 - 2033 (USD Million)
  • Table 74 Argentina Artificial Retina Market, by Disease Indication, 2027 - 2033 (USD Million)
  • Table 75 Argentina Artificial Retina Market, by End Use, 2027 - 2033 (USD Million)
  • Table 76 Brazil Artificial Retina Market, by Product, 2027 - 2033 (USD Million)
  • Table 77 Brazil Artificial Retina Market, by Disease Indication, 2027 - 2033 (USD Million)
  • Table 78 Brazil Artificial Retina Market, by End Use, 2027 - 2033 (USD Million)
  • Table 79 Middle East & Africa Artificial Retina Market, by Country, 2027 - 2033 (USD Million)
  • Table 80 Middle East & Africa Artificial Retina Market, by Product, 2027 - 2033 (USD Million)
  • Table 81 Middle East & Africa Artificial Retina Market, by Disease Indication, 2027 - 2033 (USD Million)
  • Table 82 Middle East & Africa Artificial Retina Market, by End Use, 2027 - 2033 (USD Million)
  • Table 83 Saudi Arabia Artificial Retina Market, by Product, 2027 - 2033 (USD Million)
  • Table 84 Saudi Arabia Artificial Retina Market, by Disease Indication, 2027 - 2033 (USD Million)
  • Table 85 Saudi Arabia Artificial Retina Market, by End Use, 2027 - 2033 (USD Million)
  • Table 86 South Africa Artificial Retina Market, by Product, 2027 - 2033 (USD Million)
  • Table 87 South Africa Artificial Retina Market, by Disease Indication, 2027 - 2033 (USD Million)
  • Table 88 South Africa Artificial Retina Market, by End Use, 2027 - 2033 (USD Million)
  • Table 89 UAE Artificial Retina Market, by Product, 2027 - 2033 (USD Million)
  • Table 90 UAE Artificial Retina Market, by Disease Indication, 2027 - 2033 (USD Million)
  • Table 91 UAE Artificial Retina Market, by End Use, 2027 - 2033 (USD Million)
  • Table 92 Kuwait Artificial Retina Market, by Type, 2027 - 2033 (USD Million)
  • Table 93 Kuwait Artificial Retina Market, by Disease Indication, 2027 - 2033 (USD Million)
  • Table 94 Kuwait Artificial Retina Market, by End Use, 2027 - 2033 (USD Million)

List of Figures

  • Fig. 1 Information procurement
  • Fig. 2 Primary research pattern
  • Fig. 3 Market research approaches
  • Fig. 4 Value chain-based sizing & forecasting
  • Fig. 5 Market formulation & validation
  • Fig. 6 Artificial retina market segmentation
  • Fig. 7 Market driver analysis (Current & future impact)
  • Fig. 8 Market restraint analysis (Current & future impact)
  • Fig. 9 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 10 Porter's Five Forces Analysis
  • Fig. 11 Artificial retina market, product outlook key takeaways (USD Million)
  • Fig. 12 Artificial retina market: product movement analysis (USD Million), 2027 & 2033
  • Fig. 13 Epiretinal implants market revenue estimates and forecasts, 2027 - 2033 (USD Million)
  • Fig. 14 Subretinal implants market revenue estimates and forecasts, 2027 - 2033 (USD Million)
  • Fig. 15 Suprachoroidal implants market revenue estimates and forecasts, 2027 - 2033 (USD Million)
  • Fig. 16 Artificial retina market, disease indication outlook key takeaways (USD Million)
  • Fig. 17 Artificial retina market: disease indication movement analysis (USD Million), 2027 & 2033
  • Fig. 18 Retinitis pigmentosa market revenue estimates and forecasts, 2027 - 2033 (USD Million)
  • Fig. 19 Dry age-related macular degeneration (AMD) (geographic atrophy) market revenue estimates and forecasts, 2027 - 2033 (USD Million)
  • Fig. 20 Stargardt disease market revenue estimates and forecasts, 2027 - 2033 (USD Million)
  • Fig. 21 Other inherited retinal dystrophies (IRD) market revenue estimates and forecasts, 2027 - 2033 (USD Million)
  • Fig. 22 Artificial retina market, end use outlook key takeaways (USD Million)
  • Fig. 23 Artificial retina market: end use movement analysis (USD Million), 2027 & 2033
  • Fig. 24 Hospitals market revenue estimates and forecasts, 2027 - 2033 (USD Million)
  • Fig. 25 Specialty eye clinics market revenue estimates and forecasts, 2027 - 2033 (USD Million)
  • Fig. 26 Others market revenue estimates and forecasts, 2027 - 2033 (USD Million)
  • Fig. 27 Artificial retina market, regional key takeaways (USD Million)
  • Fig. 28 Artificial retina market regional outlook, 2026 & 2033, USD Million
  • Fig. 29 North America artificial retina market estimates and forecasts, 2027 - 2033 (USD Million)
  • Fig. 30 U.S. artificial retina market estimates and forecasts, 2027 - 2033 (USD Million)
  • Fig. 31 Canada artificial retina market estimates and forecasts, 2027 - 2033 (USD Million)
  • Fig. 32 Mexico artificial retina market estimates and forecasts, 2027 - 2033 (USD Million)
  • Fig. 33 Europe artificial retina market estimates and forecasts, 2027 - 2033 (USD Million)
  • Fig. 34 UK artificial retina market estimates and forecasts, 2027 - 2033 (USD Million)
  • Fig. 35 Germany artificial retina market estimates and forecasts, 2027 - 2033 (USD Million)
  • Fig. 36 France artificial retina market estimates and forecasts, 2027 - 2033 (USD Million)
  • Fig. 37 Italy artificial retina market estimates and forecasts, 2027 - 2033 (USD Million)
  • Fig. 38 Spain artificial retina market estimates and forecasts, 2027 - 2033 (USD Million)
  • Fig. 39 Denmark artificial retina market estimates and forecasts, 2027 - 2033 (USD Million)
  • Fig. 40 Sweden artificial retina market estimates and forecasts, 2027 - 2033 (USD Million)
  • Fig. 41 Norway artificial retina market estimates and forecasts, 2027 - 2033 (USD Million)
  • Fig. 42 Russia artificial retina market estimates and forecasts, 2027 - 2033 (USD Million)
  • Fig. 43 Asia Paciifc artificial retina market estimates and forecasts, 2027 - 2033 (USD Million)
  • Fig. 44 Japan artificial retina market estimates and forecasts, 2027 - 2033 (USD Million)
  • Fig. 45 China artificial retina market estimates and forecasts, 2027 - 2033 (USD Million)
  • Fig. 46 India artificial retina market estimates and forecasts, 2027 - 2033 (USD Million)
  • Fig. 47 Australia artificial retina market estimates and forecasts, 2027 - 2033 (USD Million)
  • Fig. 48 South Korea artificial retina market estimates and forecasts, 2027 - 2033 (USD Million)
  • Fig. 49 Thailand artificial retina market estimates and forecasts, 2027 - 2033 (USD Million)
  • Fig. 50 Singapore artificial retina market estimates and forecasts, 2027 - 2033 (USD Million)
  • Fig. 51 Malaysia artificial retina market estimates and forecasts, 2027 - 2033 (USD Million)
  • Fig. 52 Taiwan artificial retina market estimates and forecasts, 2027 - 2033 (USD Million)
  • Fig. 53 Vietnam artificial retina market estimates and forecasts, 2027 - 2033 (USD Million)
  • Fig. 54 Philippines artificial retina market estimates and forecasts, 2027 - 2033 (USD Million)
  • Fig. 55 Latin America artificial retina market estimates and forecasts, 2027 - 2033 (USD Million)
  • Fig. 56 Brazil artificial retina market estimates and forecasts, 2027 - 2033 (USD Million)
  • Fig. 57 Argentina artificial retina market estimates and forecasts, 2027 - 2033 (USD Million)
  • Fig. 58 Middle East & Africa artificial retina market estimates and forecasts, 2027 - 2033 (USD Million)
  • Fig. 59 South Africa artificial retina market estimates and forecasts, 2027 - 2033 (USD Million)
  • Fig. 60 Saudi Arabia artificial retina market estimates and forecasts, 2027 - 2033 (USD Million)
  • Fig. 61 UAE artificial retina market estimates and forecasts, 2027 - 2033 (USD Million)
  • Fig. 62 Kuwait artificial retina market estimates and forecasts, 2027 - 2033 (USD Million)
  • Fig. 63 List of key emerging company's/indication disruptors/innovators